> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Hospira Recalls 1 Bleomycin Lot
- URL: https://www.fdaweb.com/hospira-recalls-1-bleomycin-lot/
- Published: 2024-01-02T12:00:00.000Z
- Updated: 2026-09-14T14:19:06.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5156040

FDA says Hospira has recalled one lot of bleomycin for injection, USP 15 units single dose Onco-Tain glass fliptop vial, due to a confirmed customer report for the presence of glass particulate within a single vial. The agency [notice](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/hospira-inc-issues-voluntary-nationwide-recall-one-lot-bleomycin-injection-usp-15-units-single-dose?ref=fdaweb.com) says that to date no adverse event reports related to the recall have been received.

Bleomycin for injection is described as a mixture of cytotoxic glycopeptide antibodies isolated from a strain of *Streptomyces verticillus*. Hospira says it should be considered to be a palliative treatment useful in the management of the neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents.